Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORAY: Vepugratinib in Bladder Cancer and Upper Tract Urothelial Carcinoma
NCT07827612Phase 2Not yet recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
A Phase 2 trial of vepugratinib in non-muscle-invasive bladder cancer (NMIBC), upper tract urothelial carcinoma (UTUC), sponsored by Eli Lilly and Company. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
vepugratinib
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on NCT07827612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07827612.